<DOC>
	<DOC>NCT00095108</DOC>
	<brief_summary>This study is being done to see if an experimental drug called recombinant interleukin-21 (rIL-21) when given to patients with stage 4 malignant melanoma or stage 4 kidney cancer is safe and has any effect on these types of cancers.</brief_summary>
	<brief_title>Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer</brief_title>
	<detailed_description>This is a phase 1 safety study. Everyone enrolled and eligible will be given rIL-21. The study has 2 parts, Part A will determine how high a dose of rIl-21 can be safely given to patients with these types of cancers. Part B will determine if the drug is of any benefit to patients with these types of cancers. Part A may have up to 7 different dose groups. Beginning with the lowest dose, 3 patients will be treated and will be watched for side effects. If the side effects are not severe, the next group of 3 patients will recieve a higher dose. This cycle is repeated until the highest tolerated dose group is found.</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<criteria>18 years and older with stage 4 metastatic malignant melanoma or stage 4 metastatic kidney cancer ECOG status of 0 or 1 Patients must have adequate liver, kidney and bone marrow function Known ocular melanoma Suspected or confirmed brain metastases Patient cannot have had a bone marrow transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Metastatic Melanoma</keyword>
	<keyword>Metastatic Renal Cell Carcinoma</keyword>
</DOC>